BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1×1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA.
Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ET
Location: Regis
A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company’s website at: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Carl Mauch
[email protected]
Sarah Spencer
[email protected]
